Animal genetics determines the theoretical performance potential of the animals and the maximum starting quality of our products. It is therefore essential for the efficiency of production by means of performance factors such as lay rate and feed consumption or health factors such as body condition and feathering. By determining the potential for egg weight, shell stability, shell structure, and fertilization rate, genetics are also a significant factor in the quality of our production.
Whereas in the area of clean eggs production we use breeds that are also otherwise used in the production of eggs for human consumption, in the area of SPF production we use animal genetics specifically tailored to the requirements of vaccine production, which are regularly improved and refreshed.
We do this in cooperation with our sister company Lohmann Breeders, which specializes in hybrid breeding. Lohmann Breeders gives us exclusive access to their pure lines and works with us to select the most suitable breeding animals based on their research results.

Better vaccine yield

In our case, genetic research primarily pursues the goal of improving vaccine yield per egg used while making egg production sustainable through lower resource use or higher resource efficiency.
This overall goal is composed of many individual breeding goals and their respective importance (priorities). The combination of all breeding objectives and their respective importance are defined in a breeding index . The breeding index is the basis for which animals are ultimately selected as the basis for the production of VALO BioMedia SPF eggs.
The selected animals or their descendants are subsequently “purified for 3 years” according to the requirements of the European Pharmacopoeia, Chapter 5.2.2. or the United States Department of Agriculture Veterinary Services Memorandum 800.65 and crossed in a further generation before the SPF eggs are allowed to be sold as such.

Success monitoring

We record all our production data digitally and in detail worldwide. This gives us a detailed view of the performance of the animals in production as well as selected quality parameters of the SPF eggs (such as fertilization rates, shell stability).

In addition, we receive structured feedback from our customers on the results the eggs have yielded in vaccine production or research trials.

Based on the data collected internally and externally, we discuss with the geneticists at Lohmann Breeders what the breeding index for the next generation of SPF genetics should look like.

We repeat this cycle every 2 years so that refreshed genetics are available for production every 2 years as well.


High-quality feed is the basic prerequisite for the health of the animals and for them to be able to reach their genetic performance potential. The composition of the feed according to the age of the animals is also a decisive factor in ensuring that the eggs meet the set requirements in terms of the following factors: size, weight, shell stability, and shell structure.

Furthermore, in the SPF area, feed represents a significant risk for the introduction of undesirable pathogens. To minimize this risk, we rely on our own feed mill to supply our SPF stocks in Europe. It is located in the north of Germany and enables us to achieve the best possible feed safety and quality through the selection of raw material quality, thermal treatment, and all associated delivery and distribution procedures. This is also documented by the certifications according to GMP+ B1, HACCP, ISO 9001:2015.

We ensure equally high feed quality and safety for our SPF animals in the U.S. and Brazil through feed mills operated by our sister company at the highest level of hygiene.

In the area of clean egg production, we work with external, local feed mills that are first approved by us through audits and then regularly audited.

Infrastructure and processes

We continuously invest in both the physical and IT infrastructure of our production. This applies to all locations and products and is carried out with the aim of high-quality and efficient production with the best biosecurity and the highest animal welfare standards.

Regular investments are also made in the continuous further development of disinfection, sorting, incubation and distribution processes at all locations. In this way, we make each of these processes more sustainable and more efficient in terms of higher vaccine yield.


The starting point for any further development is the live data that we continuously generate and evaluate in our production processes. They give us the opportunity to identify and realize potential for improvement in the production process at an early stage. We incorporate our customers' data to ensure a comprehensive assessment of the process chain. Because we are pursuing the common goal of being able to produce more vaccine doses with fewer eggs in the end.